Chien Sun, PhD
シニアプリンシパル
Expertise:
With a strong background in biomedical engineering, Chien has been advising life science clients on product launch, market access strategy, growth strategy, and life cycle management for many years. He has particular expertise in cancer therapeutics, diagnostics, and nanotechnology.
Prior to joining EVERSANA, Chien consulted in the life sciences division at L.E.K. Consulting and led engagements that spanned landscape assessment, value-maximizing strategy, growth strategy, and asset evaluation for leading pharmaceutical and diagnostics companies. He previously was the chief operating officer for The Center for Cell Control, a regional nanomedicine development center funded by the National Institutes of Health, where he led a multi-institutional team of researchers from the University of California at Los Angeles, University of California at Berkeley, and Stanford University. He also founded and served as chief research and development officer for Synlixir Therapeutics, a biotech startup focused on developing combination therapies for early-stage cancers.
Chien received his MS (instrumentation and sensors) and PhD (cancer therapeutics) in biomedical engineering from the University of California at Los Angeles where he was the recipient of the Outstanding MS Award and the Outstanding PhD Award at graduation. As a postdoctoral scholar at UCLA, he developed a novel patented multi-drug platform for the treatment of cancer, eradication of infection, and the differentiation of stem cells. Chien additionally holds a bachelor’s degree in biological sciences from the University of California at Irvine where he graduated Phi Beta Kappa along with other high honors.
Articles by Chien Sun, PhD
High-Efficiency Commercialization for High-Science Brands
High-stake or complex therapies, such as cell and gene therapies, immunotherapies and RNA interference (RNAi), have the potential to change the course of treatment for cancer patients and patients with rare diseases. But first, pharma companies must work with providers to navigate patient access complications and distribute these life-saving treatments in a timely manner. While physicians, patients and caregivers fight complex and rare diseases, a growing number of drug manufacturers are fighting to get their high-science therapies to market at rapid rates. As a result, it is exceedingly difficult and time-consuming, especially for first-time pharma companies, to launch high-science brands. The only options until now were raising the capital to go at it alone, selling, or licensing their product with larger […]